Cassava Sciences Inc (SAVA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cassava Sciences Inc (SAVA) has a cash flow conversion efficiency ratio of -0.130x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.88 Million) by net assets ($68.14 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Cassava Sciences Inc stock valuation for the company's overall valuation and market capitalisation.
Cassava Sciences Inc - Cash Flow Conversion Efficiency Trend (1999–2025)
This chart illustrates how Cassava Sciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Cassava Sciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cassava Sciences Inc ranked by their cash flow conversion efficiency. Explore Cassava Sciences Inc (SAVA) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Garo AB
ST:GARO
|
0.070x |
|
Seresco S.A.
MC:SCO
|
0.137x |
|
Azevedo & Travassos S.A
SA:AZEV3
|
0.168x |
|
NFON AG
XETRA:NFN
|
0.024x |
|
Muda Holdings Bhd
KLSE:3883
|
0.000x |
|
Sanifoam Sunger Sanayi ve Ticaret AS
IS:SANFM
|
-0.008x |
|
Gezinomi Seyahat Turizm Ticaret AS
IS:GZNMI
|
0.366x |
|
Aran Research and Development 1982 Ltd
TA:ARAN
|
0.384x |
Annual Cash Flow Conversion Efficiency for Cassava Sciences Inc (1999–2025)
The table below shows the annual cash flow conversion efficiency of Cassava Sciences Inc from 1999 to 2025. View Cassava Sciences Inc stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $74.40 Million | $-32.25 Million | -0.433x | +45.98% |
| 2024-12-31 | $145.70 Million | $-116.93 Million | -0.803x | -34.49% |
| 2023-12-31 | $137.47 Million | $-82.03 Million | -0.597x | -75.15% |
| 2022-12-31 | $227.54 Million | $-77.51 Million | -0.341x | -186.46% |
| 2021-12-31 | $253.91 Million | $-30.20 Million | -0.119x | -103.73% |
| 2020-12-31 | $92.20 Million | $-5.38 Million | -0.058x | +48.69% |
| 2019-12-31 | $22.10 Million | $-2.51 Million | -0.114x | +53.19% |
| 2018-12-31 | $19.63 Million | $-4.77 Million | -0.243x | +71.38% |
| 2017-12-31 | $9.70 Million | $-8.24 Million | -0.849x | -29.37% |
| 2016-12-31 | $18.64 Million | $-12.23 Million | -0.656x | -112.94% |
| 2015-12-31 | $29.37 Million | $-9.05 Million | -0.308x | -29.31% |
| 2014-12-31 | $40.06 Million | $-9.55 Million | -0.238x | -65.75% |
| 2013-12-31 | $48.30 Million | $-6.95 Million | -0.144x | +73.65% |
| 2012-12-31 | $13.14 Million | $-7.17 Million | -0.546x | -9220.90% |
| 2011-12-31 | $44.39 Million | $-260.00K | -0.006x | -34.88% |
| 2010-12-31 | $32.93 Million | $-143.00K | -0.004x | +96.80% |
| 2009-12-31 | $108.25 Million | $-14.69 Million | -0.136x | -226.78% |
| 2008-12-31 | $104.29 Million | $11.16 Million | 0.107x | +398.57% |
| 2007-12-31 | $103.91 Million | $2.23 Million | 0.021x | +114.14% |
| 2006-12-31 | $77.92 Million | $-11.83 Million | -0.152x | -108.49% |
| 2005-12-31 | $63.36 Million | $113.23 Million | 1.787x | +612.48% |
| 2004-12-31 | $93.40 Million | $-32.57 Million | -0.349x | -30.19% |
| 2003-12-31 | $76.56 Million | $-20.51 Million | -0.268x | +13.20% |
| 2002-12-31 | $50.22 Million | $-15.50 Million | -0.309x | -63.67% |
| 2001-12-31 | $65.62 Million | $-12.37 Million | -0.189x | -100.90% |
| 2000-12-31 | $78.69 Million | $-7.39 Million | -0.094x | +68.16% |
| 1999-12-31 | $9.14 Million | $-2.69 Million | -0.295x | -- |
About Cassava Sciences Inc
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Cassav… Read more